Endometrial Cancer

>

Latest News

FDA Approves Pembrolizumab Plus Chemo for Advanced or Recurrent Endometrial Cancer
FDA Approves Pembrolizumab Plus Chemo for Advanced or Recurrent Endometrial Cancer

June 17th 2024

The approval of this pembro-chemo combination for adults with primary advanced or recurrent endometrial carcinoma includes those with mismatch repair-proficient or -deficient disease.

FDA Approves Durvalumab-Chemo Regimen for Advanced or Recurrent dMMR Endometrial Cancer
FDA Approves Durvalumab-Chemo Regimen for Advanced or Recurrent dMMR Endometrial Cancer

June 14th 2024

Estrogen Therapy May Impact Ovarian/Endometrial Cancer Incidence in Postmenopausal Women After Hysterectomy
Estrogen Therapy May Impact Ovarian/Endometrial Cancer Incidence in Postmenopausal Women After Hysterectomy

May 24th 2024

Adverse Effect Management for Immunotherapies in Advanced Endometrial Cancer
Adverse Effect Management for Immunotherapies in Advanced Endometrial Cancer

May 13th 2024

Dostarlimab/Chemo Receives Priority Review to Expand Indication in Endometrial Cancer
Dostarlimab/Chemo Receives Priority Review to Expand Indication in Endometrial Cancer

May 12th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.